Xin Lang Cai Jing·2025-09-05 03:16Company Overview - 康希诺生物股份公司 is located in Tianjin Economic-Technological Development Area and was established on January 13, 2009. The company went public on August 13, 2020. Its main business involves the research, production, and commercialization of innovative vaccines that meet both Chinese and international standards [1][2]. Financial Performance - As of June 30, 康希诺 reported a revenue of 382 million yuan for the first half of 2025, representing a year-on-year growth of 26% [2]. - The company recorded a net profit attributable to shareholders of -13.49 million yuan, which is a 94.02% increase compared to the previous period [2]. - Since its A-share listing, 康希诺 has distributed a total of 198 million yuan in dividends, with no dividends paid in the last three years [3]. Stock Performance - On September 5, 康希诺's stock price increased by 2.01%, reaching 81.30 yuan per share, with a trading volume of 84.25 million yuan and a turnover rate of 0.91%. The total market capitalization is 20.118 billion yuan [1]. - Year-to-date, 康希诺's stock price has risen by 33.17%, but it has seen a decline of 1.38% over the last five trading days and 2.93% over the last 20 days. In the last 60 days, the stock price increased by 34.49% [1]. Shareholder Information - As of June 30, 康希诺 had 17,500 shareholders, a decrease of 1.92% from the previous period. The average number of circulating shares per shareholder remains at 0 [2]. Business Segments - The company's main revenue source comes from vaccine and related product sales, accounting for 97.84% of total revenue, while other supplementary income constitutes 2.16% [1]. - 康希诺 operates within the pharmaceutical and biological industry, specifically in the vaccine sector, and is involved in concepts such as anti-influenza and monkeypox [1].